Our 2022 Progress Report articulates our approach to access to medicines and highlights key initiatives aimed at broadening access in LMICs by building sustainable capacity, creating innovative affordability programs and collaborating with policymakers to drive meaningful change.
Download the 2022 Access to Medicines Progress Report
Download Access to Medicines progress highlights
Access to Medicines Progress Report 2020
Access to Medicines Progress Report 2018
As a patient-focused, values-based, R&D-driven global biopharmaceutical company, Takeda is committed to discovering and delivering life-transforming medicines and vaccines to patients regardless of where they live or what they can afford to pay. We're committed to broadening our end-to-end access work to address barriers to access treatment.
We adapt international know-how to meet the unique needs of local healthcare systems, working to understand and address healthcare infrastructure and capacity across the entire patient journey.
We mobilize collective efforts within and outside our organization to make a meaningful difference to the lives of patients and their local communities. Here is a story of a patient supported by our Access to Medicines programs in the Philippines.
Our signature Blueprint for Innovative Healthcare Access mobilizes collective action to address access barriers and enhance local care for patients living with non-communicable diseases in LMICs.